Medinet ＜2370＞ announced financial results for the 2nd quarter (23/10/24 to 3/24) of the fiscal year ending 2024/9 on the 10th. Net sales increased 14.4% from the same period last year to 399 million yen, operating loss was 658 million yen (loss of 671 million yen in the same period last year), ordinary loss was 632 million yen (loss of 669 million yen), and quarterly net loss was 634 million yen (loss of 676 million yen).

Sales in the cell processing business increased 14.4% from the same period last year to 399 million yen, and segment loss was 154 million yen (loss of 133 million yen in the same period last year). We are actively developing activities to expand our three business areas (specific cell processed product manufacturing, CDMO business, value chain business). During this 2nd quarter cumulative period, sales have increased in the specific cell processed product manufacturing industry due to a recovery in the number of immune cell processing contracts, price revisions with some business partners, lump-sum technology transfer payments, etc. for manufacturing contracts, etc., and price revisions for manufacturing contract fees in the CDMO business.

Sales in the regenerative medicine products business fell 39.7% to 50 billion yen, and segment losses were 219 million yen (loss of 225 million yen) due to a decrease in research and development expenses. In addition to aiming for early monetization of regenerative medicine products, etc., they are also paying attention to development trends of regenerative medicine products carried out domestically and internationally, and are carrying out activities with a view to acquiring and expanding these pipelines.

As for the full-year earnings forecast for the fiscal year ending 2024/9, the initial plan for sales is 850 million yen, up 28.5% from the previous fiscal year, operating loss is 1,488 billion yen, ordinary loss is 1,475 billion yen, and net loss of 1,479 billion yen remains unchanged.